Anirban Maitra: The phase 1 data of Genentech’s KRAS G12C inhibitor Divarasib was published yesterday in NEJM.
“The phase 1 data of Genentech’s KRAS G12C inhibitor Divarasib was published yesterday in nejm. Mostly Lung Cancer, Colorectal Cancer where G12C predominates, followed by a sprinkling of other solid cancer types like Pancreatic Cancer.
Interesting Liquid Biopsy correlatives showing that genetic mechanisms of resistance to allele specific KRASi play a role in both intrinsic & acquired resistance. In some cases there were pre-existing KRAS non-G12C alleles detectable even at baseline in blood – not surprisingly these alleles “took over” in progressing lesions. In other cases, KRAS non-G12C alleles (and various non KRAS mutations such as in NRAS or amplifications like MET) were acquired during therapy. For a subset of these RAS-centric genomic resistance mechanisms allele agnostic inhibitors like the RevMed compound will hopefully have a more sustained duration of response. Eager to see how this plays out in the ensuing months.”
For the article click here.
Source: Anirban Maitra/Twitter
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023